Lung Cancer Awareness Month 2024
“Lung cancer is the most common cancer type and the most common cause of cancer death in the world. The most recent global estimates from the International Agency for Research on Cancer (IARC) indicate that in 2022 almost 2.5 million people were diagnosed with lung cancer and more than 1.8 million people died from the disease. Lung cancer causes more than twice as many deaths as colorectal cancer, which is the second most common cause of cancer death.”
“It Saved My Life:” Why Biomarker Testing is Vital
“John shares the story of his lung cancer diagnosis and how biomarker testing made all the difference.”
With smoking rates declining, so too are lung cancer deaths. For nonsmokers, the numbers tell a different story.
“November is Lung Cancer Awareness Month, which brings both good news and bad. On the one hand, overall rates of the disease — and deaths from it — have declined precipitously as smoking rates have plummeted. But, on the other hand, diagnoses are climbing among people who have never smoked.”
Circulating Tumor DNA Presence Associated With Consolidation Immunotherapy Outcomes in NSCLC
“For patients with inoperable stage III non-small cell lung cancer (NSCLC), measuring circulating tumor DNA (ctDNA) may help personalize the duration of consolidation immunotherapy, according to a recent analysis published in the Journal of Thoracic Oncology.”
Perioperative Chemoimmunotherapy Shows Long-Term Benefits in Lung Cancer
“Key Takeaways – Chemoimmunotherapy shows promising long-term benefits for resectable NSCLC, with 65% five-year progression-free survival and 69.3% overall survival. Protocol adherence significantly improves outcomes, with 75.4% progression-free survival and 78% overall survival in the per-protocol group.”
